Pfizer Limited
Pfizer Limited, a subsidiary of the global pharmaceutical giant Pfizer Inc., is headquartered in India and operates extensively across the Asia-Pacific region. Founded in 1849, Pfizer has established itself as a leader in the pharmaceutical industry, focusing on innovative medicines and vaccines that address critical health challenges. The company is renowned for its diverse portfolio, which includes treatments in areas such as oncology, cardiology, immunology, and infectious diseases. Pfizer Limited's commitment to research and development has led to significant breakthroughs, making its products unique in efficacy and safety. With a strong market position, Pfizer Limited has achieved numerous accolades for its contributions to healthcare, including the rapid development of vaccines during public health emergencies. This dedication to improving patient outcomes solidifies its reputation as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Pfizer Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pfizer Limited's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pfizer Limited's reported carbon emissions
In 2024, Pfizer Limited reported total carbon emissions of approximately 2,475,000 kg CO2e for Scope 2 and 57,000 kg CO2e for Scope 1 in India. This reflects a significant commitment to reducing their carbon footprint, with a notable reduction in carbon intensity per million tablets produced, decreasing from 0.98 tonnes CO2e to 0.72 tonnes CO2e, representing a 26% reduction from 2023 to 2024. In 2023, the company’s emissions were recorded at 3,653,000 kg CO2e for Scope 2 and 63,000 kg CO2e for Scope 1. This indicates a proactive approach to managing and mitigating their environmental impact, particularly in the pharmaceutical sector, where emissions can be substantial. Pfizer Limited has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. However, their focus on reducing Scope 1 and 2 emissions demonstrates a commitment to sustainability and climate responsibility. The company's emissions data is not cascaded from a parent organization, indicating that these figures are independently reported. Pfizer Limited's ongoing initiatives and targets reflect a strategic approach to achieving lower carbon emissions and enhancing their overall sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 149,000 | 00,000 |
| Scope 2 | 3,433,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
